Anavex Life Sciences Corporation (AVXL) Options

The right decision.

The UK system is struggling to provide basic health services and spending huge sums on a boutique therapy with minimal effectiveness, high risk and exorbitant cost is not the right thing to do.

This piece reads as a company paid promo.,

Nice post, Hosai. Lecanemab, made by Eisai, and donanemab, made by Eli Lilly are crap drugs in the CNS space. They do not have the safety drug trial results that Blarcamesine has and are not endorsed by the worlds best 58 doctors / scientist in the CNS space after a peer review study like Blarcamesine is. They are sub par to Blarcamesine. Imo

Article - "NHS patients denied breakthrough Alzheimer’s drugs" (The Times - UK).

"Breakthrough drugs for Alzheimer’s will be refused for use on the NHS this week, denying the treatments to about 70,000 patients in England.
Lecanemab, made by Eisai, and donanemab, made by Eli Lilly, are the first drugs proven to slow the underlying cause of dementia, clearing toxic amyloid protein from the brain and delaying cognitive decline.
When the first positive drug trial results were announced in 2022, campaigners greeted it as “the beginning of the end” for Alzheimer’s.
Both treatments were last year given UK drugs licences, making them available privately, but the health watchdog, the National Institute for Health and Care Excellence (Nice), has repeatedly refused to recommend them for use on the NHS.
Nice is understood to be announcing its final decision this week, turning down both drugs on the grounds of cost-effectiveness. “It is the end of the road for these drugs on the NHS,” one insider said.
Hilary Evans-Newton, chief executive of Alzheimer’s Research UK, said refusal would be “deeply disappointing” and send “a damaging signal to the life sciences sector — undermining confidence in the UK as a global leader in dementia research, clinical trials and innovation, with knock-on effects for patients and the wider economy”.
She added: “These treatments are not perfect, and we recognise the challenges they pose around cost, delivery and safety. But scientific progress is incremental, and these drugs represent a vital foundation to build on.”
• UK’s most prescribed drug may reduce dementia risk by 13 per cent
Alzheimer’s affects about 600,000 of the one million people with dementia in the UK. The drugs are licensed for those in the early stages of Alzheimer’s, when they are most effective, which would have made them available to about 70,000 people in England if approved.
The treatments were shown in trials to slow the rate of decline as a result of mild to moderate Alzheimer’s by an average of about four to seven months. Some patients have reported far more dramatic results — with some even claiming it has halted their decline for years. But Nice insists the overall benefits simply do not justify the costs charged.
A year’s course of the drugs, which are administered via a drip, costs about £20,000 to £25,000, although the NHS has been offered a confidential discount on that price. The cost of scans, doctors’ appointments and the regular hospital sessions to receive an infusion means the overall price at least doubles.
In a draft document in March, Nice said: “The evidence presented so far shows neither donanemab nor lecanemab provide enough benefit to justify the substantial resources the NHS would need to commit to implement access to them.” There are also concerns about side-effects; some clinicians warn that the risk of brain bleeds are not justified by the limited benefits.
Privately, patients are charged £60,000 to £80,000 a year, according to Alzheimer’s Research UK.
Despite the cost, there is a small but growing private market for those who can afford the drugs. Eli Lilly alone said it has so far provided donanemab to about 50 private patients.
Nick Brake, 60, from Rutland in the East Midlands, was told he had Alzheimer’s last year, after a four-year battle to receive a diagnosis. He started treatment on lecanemab in February, travelling to the private Cleveland Clinic in London every fortnight to receive his infusion.
“I have no idea if it is working but you have to be positive about it and just hope it’s slowing it down,” said the father of two, who has run a series of businesses, including a café, ski chalets and a charcuterie business. “I feel much better being on it — at least we are doing something positive, rather than just sitting here thinking, ‘Oh God’.”
His wife, Nicky, 58, added: “It has been a massive boost for us. We would try anything. With all your heart, you just want everyone to have the same access.”
Dr Emer Macsweeney, chief executive of Re:Cognition Health, said she has seen a surge of interest since offering the new drugs in recent months in clinics in Bristol and London. She has even treated patients who travelled from Europe, as donanemab is not yet licensed in the EU and lecanemab received authorisation there only in April.
The US, Australia, Japan, Singapore, Taiwan, South Korea, China and several nations in the Middle East and South America have approved one or both drugs.
Macsweeney said patients who cannot afford the drugs can take part in clinical trials, which she runs on behalf of pharmaceutical clients. “The only eligibility to get onto a trial is clinical,” she added. “They are available for everybody, for free, although there is a 50 per cent chance you will be on placebo.”
Emily Pegg, medical director for Eli Lilly in the UK, said Britain would struggle to attract research and tech investment if new drugs continue to be turned down. “For us to stay competitive and become a really exceptional market that is seen as the place to come and launch a medicine, that entire [pharmaceutical] life cycle needs to function seamlessly,” she said.
“But if the patient ultimately can’t get that treatment, then fighting our corner to become one of the first markets to get an approval becomes more challenging.”

https://www.thetimes.com/uk/healthcare/article/breakthrough-alzheimers-drugs-will-not-be-available-on-the-nhs-p8xqwkj29

Your probably correct Leo. Out Chartist's think it is possible to drop a buck maybe. All of us of course hope that doesn't happen but we for sure will fluctuate.
Good Luck
John k9uwa

Anyone have the info when Anavex will be presenting at this year's AAIC ??? Also what will the topic be ???? TIA

No problem, hnbadger1.

The article is worthy of rep's. More the merrier!

WGT!

Sorry xodcode , I didn’t see that you already posted the cell paper.
WGT

About 400 shares traded @ 8.37
before someone decided to paint the weekend @ 7.93 with that late 100 shares.

VWAP (which I follow especially in low volume environments) was 8.06.

How will Monday open relative to THAT SP?
I still feel there is time to await 7.50 ish prior to participating in the next bounce.

George…I expected nothing else in your emoji response. Thanks for confirming that knowledge base.

Michael Tavares on FB- Nice mention in this new paper's conclusion:
"Thus, given the current mixed success of amyloid-targeting strategies, therapies aimed at improving lysosomal and autophagy function could represent complementary or alternative approaches. One promising example is Blarcamesine, a sigma-1 and muscarinic receptor agonist, which enhances waste clearance through autophagy. A recent Phase 2B/3 trial in early AD reported a 36% slowing of clinical progression - outperforming
Lecanemab - alongside reduced brain atrophy and no amyloid-related imaging abnormalities
[128], offering promise for (combined) therapeutic intervention."

https://www.cell.com/trends/neurosciences/pdf/S0166-2236(25)00102-X.pdf

There was an 8-K filing today regarding the ASM vote. Why did he choose to file it after hours on a Friday for something so trivial? Not sure what kind of game Misleading is playing.

Combined? We don't need to combine with anyone. We become SOC.

Likin' this:

Nice mention in this new paper's conclusion: "Thus, given the current mixed success of amyloid-targeting strategies, therapies aimed at improving lysosomal and autophagy function could represent complementary or alternative approaches. One promising example is Blarcamesine, a sigma-1 and muscarinic receptor agonist, which enhances waste clearance through autophagy. A recent Phase 2B/3 trial in early AD reported a 36% slowing of clinical progression – outperforming Lecanemab – alongside reduced brain atrophy and no amyloid-related imaging abnormalities [128], offering promise for (combined) therapeutic intervention."
[https://www.cell.com/.../pdf/S0166-2236(25)00102-X.pdf]

and yes, WGT!

Plex Rec
Thanks from this Lisdexic AVXL Long

Ah Yes Mike and Steve. I doubt we see much action until the CLOCK starts counting again. Clues the other day from ASM is about all we will get until CHMP says Clock is started again. Every day that goes by is a good day. Today considering all the market.... it could have been worse.
Notice the vertical line for MOC today is RED. Notice the color and trades around MOC prior and after. Click on the small charts off to the right. Some buys/sells in black and some in red. Some of the later bids are well above our closing price. Strange 441K for the day. 40K at PRE open in blue and 50K at close in red.

WGT
John k9uwa

I actually do remember your comment after someone on "Stock Twitter" had called for an immediate sharp drop in price and you gave your comment about the process of building a Head & Shoulders Top with a lower right shoulder and the expectation of an immediate collapse in price....he presented a chart which was basically dead wrong, but he was certainly just making a call, that's his right and yours, too!

I did not agree then nor do I now!

It's possible that the multiple bottoms around the $7 region will indeed fail, but for now I continue to expect more upside with no guarantee...

Say hello to "Paddy" if I remember his name

Me 2.👍️

bcb--" the looming threat of 1-73 Top Line data release"----you must mean "3-71" !!!!! OOPS

Talking to yourself again?

Expect AVXL to close at or near the low of the day.

Tom and Sab
“Is there any reason why 8 dollars should hold strong now….”
Man, I love it when you two post your back-and-forths.
I think it is a piece of cake (and quite profitable) for the short interest to hold about $8.20 plus or minus about $0.30 until cob OPEX 20 June. No strain at all and no need to expend but little ammo.
I also believe that the looming threat of 1-73 Top Line data release has them feeling trapped into making their big move pretty quick after OPEX and then move on to a long AVXL position.
As such, I think we will see that quick $buck down you envision, plus quite a bit more when they make their move. Within the chaos and multiple capitulations, I perceive the opportunity to robust my holdings and go fat, dumb, and extremely happy forward to 1-73 great data and 2-73 EMA approval (I’m already fat and dumb, however, it is worth the investment increase to move forward to extremely happy).

As of today, you have the pressure on the markets and this stock....so you have the better "odds"....we wait and maybe we hear something about the famous Clock Stop One.

What? I'm living the dream! Unfortunately, it's the Groundhog Day dream of contstantly seeing the same thing over and over - of AVXL becoming an $8 stock.

Would that be the very good news we were to expect from the Anavex Life Sciences ASM Call this week?

I have certainly noticed that $AVXL doesn't lend itself well to TA and message board predictions 😁 and not even to military analyst ones.

Expect very good news within the next 2 weeks for AVXL stock!!!

Good luck and GOD bless,

I hope so don't want to see Mike bitch.
John k9uwa

Not a Pro but your correct Leo. I myself in the past have bought and sold afterhours. There it is a place your buy or sell bid as a limit number. It either happens or else it doesn't happen depending on whether another buyer / seller offers shares at that price.

John k9uwa

Thanks Tom If they slam it down A Buck ... then I will be in there buying MORE.

John k9uwa

Maybe you have noticed that this stock has a habit of breaking the low slightly and then reversing....who knows maybe we see $8.15 by the close.....ha ha

Got a FILL on one of the stink bids. $7.99 pps added a few to the already full boat.
John k9uwa

Will $AVXL end the week as a $8 stock?

Yeah, Tom! It does look like they want to put out another quick blast down, to get the very meek bullish psychology broken....the low volume does not help and we are without any big guns, so I guess we have to see whether Missling throws in the towel.....or......not!

The week is ending, price is floating around 8.00/8.10 , after capping at 8.25/8.30 resistance area. Looks like a cliff edge to me ,with a dollar drop waiting to get triggered. waiting to roll over. and blast down.like it did before.
I could be guessing completely wrong here, but here's my thought logic for this picture.
In recent weeks, we watched a fair rally from the 7.20 bottom to 8.40 top, so far. The climb made a nice series of higher lows, crafting perfect little support steps, and now hits a resistance ceiling right where you'd expect it. The pullback has basic target zone 8.00/7.80/7.65, area. Watching and hoping to hold, and then launch into the next upwave at least another dollar. Target 8.75/9.00/9.25. A wave pattern like this is very basic.
What could go wrong? The larger chart picture has developed a support shoulder zone waiting right around that 7.75 area. In a perfect technical world, this 7.70 support shoulder should hold strong and become the right shoulder , that launches the continued upwave pattern. What could ever go wrong?
As we've watched the last few weeks climb the upward steps, making higher lows, holding support right where it should, a computer algorithm couldn't shape it any more perfectly to look just right. Therefore... the suspicious logic says this... the short attack needs to play a trick here. Today's little drop to test 8 dollars is like a gentle lullaby, to put people to sleep. If they wiggle it down another 10 cents on monday, it will set up the trick... The short attack would be too weak if it keeps nibbling around 7.85,/7.75... the support shoulder pattern has too much strength here. What the shorts need is a big blast down. exactly like they got a few weeks ago on that one day they plunged it down from 8.30 to 7.30. They need a 70 cent plunge, let's say from 8.00 to 7.30, 8.10 to 7.40, and cut right through the important 7.70 area, straight to 7.40/30/7.25 target. My stink bids start there , to catch that 75 cent trick. The shorts, with the help of MM's, need a trick like that to push price back into the bargain basement (7.40-7.30-7.20-7.00 ) area.
The little bitty nibbles down like today won't bust through the 7.70 support shoulder. They have to pull the trick again. The previous time they did it, they set it up by holding price just above 8 dollars, and I said... Is there any reason why 8 dollars should hold strong now. And 2 days later they slammed it down a dollar. 🎱🤔

I wish someone would check on George's inner investor - if there is one?

I was just checking on Investor's inner George!

By definition MOC trades in that Summary are ONLY
those executed @ $8.22.
those executed @ that price after 16:00 are granted "some" time to resolve.
that should be taken as placed with a MM.
Trades at other than $8.22 if LARGE are likely negotiated.

That is my understanding of how the actual mechanism works.
Not all are reported @ 16:00, but
ALL are recorded at the closing price.

Any former "pros" comment?

What is the latest FUD narrative?

Im taking a narrative cleanse break, and I have them all on ignore.

Can only roll in the mud for so long.

No and they won't. Fudsters are at it today. Fudsters should have gone away in May. Never to return!!
John k9uwa

u got trolled.

X is parodying the Naysayers

"Did they pull back"---and why would they ????????

When you are wrong again will you admit it this time?

Probably not, but if they did it would be an 8K after dark. It not then some other Friday just around the corner (perhaps)...

The EMA’s June list has been released, and Anavex is still non the list. CHMP meeting scheduled for next week, we’ll soon know if a withdrawal request has been submitted. Keep an eye out for an 8-K filing—it could be released after market close on any Friday. Misleading is sneaky. Why no update on 3-71 trial? That trial should have completed last patient last visit by end May.

It's called no posts, no news, no volume, no stock price and no interest...that's what's been going on lately, other than the occasional cheerleaders who are pumping the stock with nothing but word salads

Did they pull back their submission for approval yet?

Is it me or is the conversation on the message board “suppressed” on the new Ihub format? Theres a few stocks with new ticker symbols that only let me look them up in the new format and I think it sucks. Little by little changes made block communication between shareholders.

New Stink Bids in place.
John k9uwa

It has been a long wait for sure. When I came on here this morning, a very hopeful post (440776) that approval was imminent popped up. A bit of hope even attempted to challenge my skepticism until I realized the post was from one and a half years ago. I don’t know if Misleading is stringing us along but if I were a betting man…

All 139 shares paniced and sold this morning over Israels strikes. How many more fake shares will be generated(naked shorts) to drive fear into shareholders.

When I said black swan event I didn't think it would come the next day. Sitting tight folks, more market killing moves to come. Let us pray the July 4 rumor of a biological weapon exploding unknowingly over a very large crowd in a fireworks display killing a few hundred thousands is just that, a rumor.

blarcamesine addresses the mitochondrial, root issues, unlike the symptomatic approach of now failed competitors.
Real medicine v. literal blood letting by competition.

Approval can't come soon enough.